News
DNA sequencing could help identify relapse risk in treated AML
ATLANTA – Study uses next-generation DNA sequencing to predict risk of relapse in AML.
News
Amyloid depleter/antibody duo reduces systemic amyloidosis severity
Small, early clinical trial tests miridesap and dezamizumab.
News
Sorafenib plus chemo prolongs event-free survival in AML
ATLANTA – Updated results from the phase 2 SORAML trial support the addition of sorafenib in younger adults with newly diagnosed AML.
News
Venetoclax/rituximab boosts PFS in relapsed/refractory CLL
ATLANTA – "I believe that venetoclax/rituximab should be considered as a suitable standard therapeutic option in patients with relapsed CLL."
Video
VIDEO: Venetoclax/rituximab prolongs PFS in relapsed/refractory CLL
ATLANTA – Dr. John Seymour discussed results from a study comparing bendamustine/rituximab with venetoclax/rituximab in relapsed/refractory CLL...
Video
VIDEO: Daratumumab gives kick to standard first-line myeloma therapy
Dr. Jesus San-Miguel discusses results of the ALCYONE study and recent advances in the treatment of multiple myeloma.
News
Daratumumab plus VMP boosts PFS, MRD-negativity in de novo myeloma
ATLANTA – The study included patients with new onset multiple myeloma who were not eligible for transplant.
News
Novel PARP inhibitor boosts PFS in HER2- breast cancer with BRCA mutations
SAN ANTONIO – PARP inhibitor talazoparib was associated with a near doubling in progression-free survival when compared with single-agent...
News
Extra years of adjuvant bisphosphonate not needed in early breast cancer
SAN ANTONIO - Neither adapted disease-free survival nor overall survival were significantly better with 3 extra years of zoledronate therapy.
Video
VIDEO: CAR T cell axi-cel drives B-cell lymphomas into remission
Dr. Sattva S. Neelapu describes efforts to manage adverse events common to CAR T-cell therapies, notably cytokine release syndrome.
Video
VIDEO: CTCs may identify asymptomatic late breast cancer recurrences
Circulating tumor cells may play a role in identifying late breast cancer recurrences in otherwise asymptomatic women
News
Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomas
ATLANTA – Updated results in 108 patients with refractory B cell lymphomas showed an ORR of 82%, including 58% complete responses, after a median...
News
Sickle cell: Customized stem cells may improve transfusion efficacy, safety
ATLANTA – Matching red cell products to sickle-cell disease patients with rare Rh antibodies can be done with a little fancy stem cell footwork...
News
2 = 5 for additional AI therapy for postmenopausal HR+ breast cancer
SAN ANTONIO - Five years of additional therapy with anastrozole was no more effective than 2 additional years.